Imunon, Inc. Common Stock (IMNN)

Price$2.06

Value ScoreC

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-57.93%

Price vs S&P 500 (4W)-24.26%

VGM Score36.75

Market Capitalization$8.66M

All Metrics

Book Value / Share (Quarterly)$0.86

P/TBV (Annual)0.34x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.84

Price vs S&P 500 (YTD)-54.09%

Gross Margin (TTM)34.14%

Net Profit Margin (TTM)-6901.92%

EPS (TTM)$-5.74

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-5.74

EPS (Annual)$-1.58

ROI (Annual)-447.66%

Gross Margin (Annual)16.33%

Net Profit Margin (5Y Avg)-4275.20%

Cash / Share (Quarterly)$1.22

ROA (Last FY)-195.53%

EBITD / Share (TTM)$-4.85

ROE (5Y Avg)-173.69%

Operating Margin (TTM)-7361.54%

Cash Flow / Share (Annual)$-4.15

P/B Ratio2.58x

P/B Ratio (Quarterly)3.43x

Net Income / Employee (Annual)$-950,000

EV / Revenue (TTM)7.43x

Net Interest Coverage (TTM)-7.18x

ROA (TTM)-153.79%

EPS Incl Extra (Annual)$-1.58

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)1.15x

3-Month Avg Trading Volume0.08M

52-Week Price Return-88.72%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.94

P/S Ratio (Annual)17.31x

Asset Turnover (Annual)0.01x

52-Week High$27.65

Operating Margin (5Y Avg)-5140.80%

EPS Excl Extra (Annual)$-1.58

CapEx CAGR (5Y)69.59%

Tangible BV CAGR (5Y)51.40%

26-Week Price Return-50.00%

Quick Ratio (Annual)1.90x

13-Week Price Return-38.32%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.59x

Enterprise Value$3.86M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-29.83%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.35x

Pretax Margin (Annual)-7494.00%

Cash / Share (Annual)$2.57

3-Month Return Std Dev45.56%

Gross Margin (5Y Avg)33.75%

Net Income / Employee (TTM)$-732,100

ROE (Last FY)-447.66%

Net Interest Coverage (Annual)-4.65x

EPS Basic Excl Extra (Annual)$-1.58

P/FCF (TTM)1.44x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.74

Receivables Turnover (Annual)0.00x

ROI (TTM)-341.23%

P/S Ratio (TTM)16.65x

Pretax Margin (5Y Avg)-4956.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.94

Price vs S&P 500 (52W)-113.08%

Year-to-Date Return-45.93%

5-Day Price Return-4.19%

EPS Normalized (Annual)$-1.58

ROA (5Y Avg)-90.30%

Net Profit Margin (Annual)-7180.00%

Month-to-Date Return-5.50%

Cash Flow / Share (TTM)$-3.05

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-7658.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-163.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.74

P/TBV (Quarterly)0.34x

P/B Ratio (Annual)1.66x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)-7203.85%

Book Value / Share (Annual)$2.07

Price vs S&P 500 (13W)-46.58%

Beta1.96x

P/FCF (Annual)3.83x

Revenue / Share (TTM)$0.00

ROE (TTM)-341.23%

52-Week Low$2.04

vGradeC

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.84est. -1.13

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMNNImunon, Inc. Common Stock	C	—	F	$2.06
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Imunon Inc is a clinical-stage biotechnology company developing a non-viral DNA platform to treat various human diseases by leveraging the body's natural immune mechanisms. Its lead program, IMNN-001, is a DNA-based immunotherapy for ovarian cancer that has completed Phase II clinical trials. The company is also advancing IMNN-101, a COVID-19 booster vaccine candidate, currently in first-in-human studies.